STOCK TITAN

Terns Pharmaceuticals Inc - TERN STOCK NEWS

Welcome to our dedicated news page for Terns Pharmaceuticals (Ticker: TERN), a resource for investors and traders seeking the latest updates and insights on Terns Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Terns Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Terns Pharmaceuticals's position in the market.

Rhea-AI Summary
Terns Pharmaceuticals to participate in investor conferences in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.84%
Tags
conferences
-
Rhea-AI Summary
Terns Pharmaceuticals, Inc. (TERN) reported positive top-line data from the Phase 2a DUET trial of TERN-501 in NASH, with TERN-501 meeting all primary and secondary endpoints. TERN-701 Phase 1 clinical trial for CML on track to initiate in second half of 2023. TERN-601 program in obesity highlighted in preclinical data presented at ADA’s 83rd Annual Scientific Meeting, on track to initiate Phase 1 clinical trial in second half of 2023. Cash, cash equivalents and marketable securities of $286 million expected to provide runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.73%
Tags
-
Rhea-AI Summary
TERN-501 Phase 2a DUET trial shows dose-dependent reduction in liver fat content, with 45% reduction at 6mg dose. 64% of patients achieved >30% reduction. TERN-501 monotherapy has potential as NASH treatment. Combination with TERN-101 shows modest improvements. No safety concerns.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.73%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.8%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.8%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.17%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.39%
Tags
none
-
-
Rhea-AI Summary
Terns Pharmaceuticals will be participating in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023. The event will be webcasted live and a replay will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Terns Pharmaceuticals Inc

Nasdaq:TERN

TERN Rankings

TERN Stock Data

332.31M
26.93M
1.86%
111.26%
6.95%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Foster City

About TERN

terns pharmaceuticals is a global biopharmaceutical company committed to discovering and developing molecularly-targeted, oral, small molecule drugs to treat liver diseases and cancers. the company combines expertise in disease biology and medicinal chemistry with a capital-efficient drug discovery model and extensive clinical development capabilities in china to advance its growing pipeline of drugs that are optimized against clinically-validated targets. based in san mateo, california and shanghai, terns is focused on bringing forward innovative therapeutic candidates with the potential to address significant unmet medical needs in china and globally.